News stories about Kura Oncology (NASDAQ:KURA) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kura Oncology earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.7318513521885 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Kura Oncology (NASDAQ KURA) traded up $0.55 on Wednesday, reaching $16.60. The company had a trading volume of 278,700 shares, compared to its average volume of 180,910. The stock has a market capitalization of $501.58 and a price-to-earnings ratio of -10.71. Kura Oncology has a 12 month low of $5.78 and a 12 month high of $17.50. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). analysts predict that Kura Oncology will post -1.52 earnings per share for the current year.

A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. BidaskClub lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Wedbush assumed coverage on Kura Oncology in a research report on Tuesday, December 26th. They set a “buy” rating and a $19.00 price objective for the company. Oppenheimer set a $18.00 price objective on Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, Cann restated a “buy” rating and set a $17.50 price objective on shares of Kura Oncology in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $18.08.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Kura Oncology (KURA) Stock Price” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-kura-oncology-kura-stock-price/1810798.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.